John G. Gums

John G. Gums

Auto-generated profile, based on publicly available information

John G. Gums

College of Pharmacy, University of Florida , Gainesville, FL 32610

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MAMeghan J. Arwood
Meghan J. Arwood
EDEric Dietrich
Eric Dietrich
BDBenjamin Duong
Benjamin Duong
DSD. Max Smith
D. Max Smith
KCKelsey Cook
Kelsey Cook
JGJohn G. Gums
John G. Gums
Pharmacogenetic testing (PGT) is increasingly being used as a tool to guide clinical decisions. This article describes the development of an outpatient, pharmacist-led, pharmacogenetics consult clinic within internal medicine, its workflow, and early results, along with successes and challenges. A pharmacogenetics-trained pharmacist encouraged primary care physicians (PCPs) to refer patients who were experiencing side effects/ineffectiveness from certain antidepressants, opioids, and/or proton pump inhibitors. In clinic, the pharmacist confirmed the need for and ordered CYP2C19 and/or CYP2D6 testing, provided evidence-based pharmacogenetic recommendations to PCPs, and educated PCPs and patients on the results. Operational and clinical metrics were analyzed. In two years, 91 referred patients were seen in clinic (mean age 57, 67% women, 91% European-American). Of patients who received PGT, 77% had at least one CYP2C19 and/or CYP2D6 phenotype that would make conventional prescribing unfavorable. Recommendations suggested that physicians change a medication/dose for 59% of patients; excluding two patients lost to follow-up, 87% of recommendations were accepted. Challenges included PGT reimbursement and referral maintenance. High frequency of actionable results suggests physician education on who to refer was successful and illustrates the potential to reduce trial-and-error prescribing. High recommendation acceptance rate demonstrates the pharmacist’s effectiveness in providing genotype-guided recommendations, emphasizing a successful pharmacist–physician collaboration.

17 January 2008 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
JGJohn G Gums
John G Gums
EPElise M Pelletier
Elise M Pelletier
WBWilliam A Blumentals
William A Blumentals
Objective: To assess influenza-related secondary complications and healthcare use and costs in patients prescribed oseltamivir for influenza. Research design and methods: This study examined health insurance claims data for patients diagnosed with influenza during five influenza seasons. Patients prescribed oseltamivir were propensity matched with patients not prescribed antiviral therapy. Main outcome measures: Clinical outcomes were diagnosis with pneumonia, otitis media and hospitalizations, along with in-patient, out-patient and pharmacy use and costs. Results: Each group included 45,751 patients. Patients prescribed oseltamivir had significant reductions in the risks of pneumonia (odds ratio [OR]: 0.89, 95% CI: 0.80, 1.00), otitis media (OR: 0.84, 95% CI: 0.77, 0.91) and hospitalization (OR: 0.71, 95% CI: 0.62, 0.83). The risks of pneumonia and otitis media were also lower in children and adolescents (≤ 17 years) prescribed oseltamivir (OR: 0.74, 95% CI: 0.60, 0.91 and OR: 0.77, 95% CI: 0.69, 0.85, r...

1 December 2017
Verified
Journal Article
Closed access
AHAndrew Y Hwang
Andrew Y Hwang
TGTyler H Gums
Tyler H Gums
JGJohn G Gums
John G Gums

1 October 2009 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
SSSteven M. Smith
Steven M. Smith
SAShawn D. Anderson
Shawn D. Anderson
SWSheron Wen
Sheron Wen
YGYan Gong
Yan Gong
STStephen T. Turner
Stephen T. Turner
JGJohn G. Gums
John G. Gums

15 May 2009 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
SSSteven M Smith
Steven M Smith
JGJohn G Gums
John G Gums
Background: Fexofenadine is one of several second-generation H1-antihistamines approved for the treatment of various allergic disorders; however, it shows numerous unique properties that make it an optimal choice for many patients. Objective: To review the pharmacology, efficacy and safety of fexofenadine and the attributes differentiating it from other H1-antihistamines. Methods: We performed a literature search in PubMed/MEDLINE (1966 – March 2009) using the keywords fexofenadine, antihistamine, allergic rhinitis and chronic urticaria. We also reviewed data provided by the manufacturer in addition to reports from various governmental agencies. Results/conclusions: Fexofenadine is devoid of sedative and anticholinergic effects and may offer equivalent or greater efficacy in treating allergic disorders compared with other currently available second-generation H1-antihistamines. In addition, fexofenadine may offer cost savings over other selected H1-antihistamines owing to its recent availability in generic form in the US.

22 March 2012 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
JDJulio D Duarte
Julio D Duarte
IZIssam Zineh
Issam Zineh
BBBen Burkley
Ben Burkley
YGYan Gong
Yan Gong
TLTaimour Y Langaee
Taimour Y Langaee
JJJulie A Johnson
Julie A Johnson
Nearly one-third of the United States adult population suffers from hypertension. Hydrochlorothiazide (HCTZ), one of the most commonly used medications to treat hypertension, has variable efficacy. The renal epithelial sodium channel (ENaC) provides a mechanism for fine-tuning sodium excretion, and is a major regulator of blood pressure homeostasis. DOT1L, MLLT3, SIRT1, and SGK1 encode genes in a pathway that controls methylation of the histone H3 globular domain at lysine 79 (H3K79), thereby modulating expression of the ENaCα subunit. This study aimed to determine the role of variation in these regulatory genes on blood pressure response to HCTZ, and secondarily, untreated blood pressure. We investigated associations between genetic variations in this candidate pathway and HCTZ blood pressure response in two separate hypertensive cohorts (clinicaltrials.gov NCT00246519 and NCT00005520). In a secondary, exploratory analysis, we measured associations between these same genetic variations and untreated blood pressure. Associations were measured by linear regression, with only associations with P ≤ 0.01 in one cohort and replication by P ≤ 0.05 in the other cohort considered significant. In one cohort, a polymorphism in DOT1L (rs2269879) was strongly associated with greater systolic (P = 0.0002) and diastolic (P = 0.0016) blood pressure response to hydrochlorothiazide in Caucasians. However, this association was not replicated in the other cohort. When untreated blood pressure levels were analyzed, we found directionally similar associations between a polymorphism in MLLT3 (rs12350051) and greater untreated systolic (P < 0.01 in both cohorts) and diastolic (P < 0.05 in both cohorts) blood pressure levels in both cohorts. However, when further replication was attempted in a third hypertensive cohort and in smaller, normotensive samples, significant associations were not observed. Our data suggest polymorphisms in DOT1L, MLLT3, SIRT1, and SGK1 are not likely associated with blood pressure response to HCTZ. However, a possibility exists that rs2269879 in DOT1L could be associated with HCTZ response in Caucasians. Additionally, exploratory analyses suggest rs12350051 in MLLT3 may be associated with untreated blood pressure in African-Americans. Replication efforts are needed to verify roles for these polymorphisms in human blood pressure regulation.